On Monday, Merck announced the discontinuation of a phase 3 clinical trial combining its flagship immunotherapy Keytruda with its new molecule vibostolimab in the treatment of high-risk stage 2 to 4 melanoma.

In a press release, the US biopharmaceutical group justifies its decision by noting a high drop-out rate in patients who received both drugs compared with the control group (Keytruda alone).

In doing so, the company has followed the recommendations of the independent data monitoring committee.

Vibostolimab, not yet approved, is a compound developed by Merck that is able to activate the immune system by exerting a T-cell-mediated response against cancer cells.

Copyright (c) 2024 CercleFinance.com. All rights reserved.